Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/137314
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Cage Hydrocarbons as Linkers in Dimeric Drug Design: Case Studies with Trimethoprim and Tedizolid |
Author: | Vujcic, B. Wyllie, J. Tania, Burns, J. White, K.F. Cromwell, S. Lupton, D.W. Dutton, J. Soares da Costa, T.P. Houston, S.D. |
Citation: | Bioorganic and Medicinal Chemistry Letters, 2023; 80:129086-1-129086-5 |
Publisher: | Elsevier |
Issue Date: | 2023 |
ISSN: | 0960-894X 1464-3405 |
Statement of Responsibility: | Biljana Vujcic, Jessica Wyllie, Tania, Jed Burns, Keith F. White, Simon Cromwell, David W. Lupton, Jason L. Dutton, Tatiana P. Soares da Costa, Sevan D. Houston |
Abstract: | The looming threat of a “post-antibiotic era” has been caused by a rapid rise in antibacterial resistance and subsequent depletion of effective antibiotic agents in the clinic. An efficient strategy to address this shortfall lies in the reengineering of pre-existing and commercially available antibiotic drugs. This is exemplified by dimerization, a design concept in which two pharmacophores are covalently linked to form a new chemical entity. The cage hydrocarbons cubane (1), bicyclo[2.2.2]octane (BCO) (2), adamantane (3), and bicyclo[1.1.1]pentane (BCP) (4) present themselves as an attractive family of linkers in this regard. In this report, all four hydrocarbon cages were employed as linkers in a series of dimers based on the commercially available antibiotics trimethoprim and tedizolid. A detailed synthetic roadmap for the protection and deprotection of each pharmacophore is outlined. Several members of the trimethoprim series showed activity on par with that of their trimethoprim progenitor, although this was not the case for the tedizolid series. The design strategy outlined herein highlights the utility of the group as a platform for the rapid and modular construction of future novel antibiotics. |
Keywords: | cage hydrocarbons drug dimer trimethoprim tedizolid |
Rights: | © 2022 Elsevier Ltd. All rights reserved. |
DOI: | 10.1016/j.bmcl.2022.129086 |
Grant ID: | http://purl.org/au-research/grants/arc/FT16010007 |
Published version: | http://dx.doi.org/10.1016/j.bmcl.2022.129086 |
Appears in Collections: | Molecular and Biomedical Science publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.